Preliminary data reveals the combination of non-pegylated liposomal doxorubicin, paclitaxel and lapatinib is well tolerated with no worsening cardiac toxicity and has high antitumor activity in patients with HER2 positive primary breast cancer [18]. The gene discussed is ERBB2; the disease is breast cancer.